In a 72-year-old female who completed CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy for non‑Hodgkin lymphoma six months ago and now presents with generalized weakness, lower‑extremity edema, exertional dyspnea, jugular venous distension, laterally displaced apical impulse, a third heart sound, and a holosystolic murmur, what is the most likely cause of her symptoms?

Chemotherapy-Induced Cardiomyopathy (Anthracycline Cardiotoxicity)

This patient most likely has chemotherapy-induced cardiomyopathy (CIMP) from doxorubicin in her CHOP regimen, presenting as decompensated heart failure with left ventricular systolic dysfunction and functional mitral regurgitation.

Clinical Reasoning

The constellation of findings—generalized weakness, lower extremity edema, exertional dyspnea, jugular venous distension, laterally displaced apical impulse (indicating left ventricular dilatation), S3 gallop, and holosystolic murmur (functional mitral regurgitation from ventricular dilatation)—are classic signs of congestive heart failure 1. The critical context is her completion of CHOP chemotherapy 6 months ago.

Why Anthracycline Cardiotoxicity is the Primary Diagnosis

Doxorubicin (the "H" in CHOP) is the major culprit. The FDA explicitly warns that myocarditis, myopericarditis, pericardial effusion, and congestive heart failure—which may be fatal—have been reported with cyclophosphamide therapy 2. However, doxorubicin remains the primary cardiotoxic agent in CHOP regimens 3, 1.

The timing is consistent: CIMP can present months to years after completion of anthracycline therapy 1. Her cumulative doxorubicin dose was likely 300 mg/m² (standard for 6 cycles of CHOP), which falls within the cardiotoxic range. Research shows that 23% of patients exhibit a drop in ejection fraction >10% after CHOP therapy 4, and the risk of cardiotoxicity increases significantly with cumulative doses ≥300 mg/m² (OR=8.08) 4.

Key Risk Factors Present

This 72-year-old patient has multiple risk factors that amplify cardiotoxicity risk 2:

• Advanced age (elderly patients have increased cardiotoxicity risk)
• Cumulative anthracycline exposure (standard CHOP delivers ~300 mg/m² doxorubicin)
• Cyclophosphamide co-administration (additive cardiotoxic effect) 3

The FDA specifically states: "The risk of cardiotoxicity may be increased with high doses of cyclophosphamide, in patients with advanced age, and in patients with previous radiation treatment to the cardiac region and/or previous or concomitant treatment with other cardiotoxic agents" 2.

Clinical Presentation Details

Her physical examination findings map precisely to heart failure:

• S3 gallop: Indicates volume overload and ventricular dysfunction
• Laterally displaced apical impulse: Confirms left ventricular dilatation
• Holosystolic murmur: Functional mitral regurgitation secondary to ventricular dilatation and annular dilatation
• JVD and lower extremity edema: Right heart failure from elevated left-sided filling pressures
• Exertional dyspnea: Reduced cardiac output and pulmonary congestion

Important Diagnostic Considerations

Subclinical cardiac dysfunction is frequently missed. A systematic review found that reported heart failure increased from 1.64% to 11.72% when cardiac function was systematically evaluated post-chemotherapy (p=0.017) 5. This means many cases go undiagnosed without active surveillance.

The pooled proportion for heart failure after CHOP/R-CHOP is 4.62% (95% CI 2.25-7.65) 5, but this likely underestimates true incidence given inadequate monitoring in most studies.

Immediate Management Approach

Obtain urgent echocardiography to assess:

• Left ventricular ejection fraction (likely reduced from baseline)
• Global longitudinal strain (more sensitive than LVEF for early dysfunction) 6
• Ventricular dimensions and wall motion abnormalities
• Severity of mitral regurgitation

Check cardiac biomarkers:

• High-sensitivity troponin I (expected to be elevated) 6
• NT-proBNP (expected to be significantly elevated) 6

Initiate guideline-directed medical therapy for heart failure immediately:

• ACE inhibitor or ARB (enalapril has specific evidence in anthracycline cardiotoxicity) 3
• Beta-blocker (carvedilol or nebivolol have cardioprotective data in this population) 3
• Diuretics for volume overload
• Consider aldosterone antagonist if LVEF significantly reduced

Evidence for Cardioprotective Therapy

Multiple RCTs demonstrate that ACE inhibitors and beta-blockers can prevent or attenuate anthracycline-induced cardiac dysfunction 3:

• Enalapril prevented LVEF decline in high-risk patients (43% vs 0% developed dysfunction, p<0.001)
• Carvedilol preserved LVEF and reduced mortality trends
• Nebivolol prevented increases in ventricular dimensions

Early intervention is critical. Studies show that timely treatment in the presymptomatic phase can mitigate progression to advanced heart failure 1, 5.

Critical Pitfalls to Avoid

1. Do not attribute symptoms solely to lymphoma recurrence without cardiac evaluation—this delays life-saving heart failure treatment
2. Do not assume normal cardiac function based on lack of symptoms during chemotherapy—cardiotoxicity often manifests months later
3. Do not overlook the functional mitral regurgitation—this is secondary to ventricular dysfunction, not primary valvular disease
4. Do not delay echocardiography—clinical diagnosis alone underestimates severity

Alternative Diagnoses (Less Likely)

While lymphoma recurrence with cardiac involvement is theoretically possible, the clinical presentation is far more consistent with CIMP:

• Lymphoma recurrence would more likely present with B symptoms, lymphadenopathy, or organ-specific masses
• The symmetric nature of findings (bilateral edema, global heart failure signs) favors a cardiomyopathic process
• The 6-month timeline post-CHOP is classic for anthracycline cardiotoxicity

The evidence overwhelmingly supports chemotherapy-induced cardiomyopathy as the diagnosis 3, 1, 2, 6, 5, 4.